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Abstract
Background: New prophylactic and therapeutic tools are needed for the treatment of herpes
simplex virus infections. Several essential oils have shown to possess antiviral activity in vitro against
a wide spectrum of viruses.
Aim: The present study was assess to investigate the activities of the essential oil obtained from
leaves of Artemisia arborescens against HSV-1 and HSV-2
Methods: The cytotoxicity in Vero cells was evaluated by the MTT reduction method. The IC50
values were determined by plaque reduction assay. In order to characterize the mechanism of
action, yield reduction assay, inhibition of plaque development assay, attachment assay, penetration
assay and post-attachment virus neutralization assay were also performed.
Results: The IC50 values, determined by plaque reduction assay, were 2.4 and 4.1 μg/ml for HSV-
1 and HSV-2, respectively, while the cytotoxicity assay against Vero cells, as determined by the
MTT reduction method, showed a CC50 value of 132 μg/ml, indicating a CC50/IC50 ratio of 55 for
HSV-1 and 32.2 for HSV-2. The antiviral activity of A. arborescens essential oil is principally due to
direct virucidal effects. A poor activity determined by yield reduction assay was observed against
HSV-1 at higher concentrations when added to cultures of infected cells. No inhibition was
observed by attachment assay, penetration assay and post-attachment virus neutralization assay.
Furthermore, inhibition of plaque development assay showed that A. arborescens essential oil
inhibits the lateral diffusion of both HSV-1 and HSV-2.
Conclusion: This study demonstrates the antiviral activity of the essential oil in toto obtained from
A. arborescens against HSV-1 and HSV-2. The mode of action of the essential oil as antiherpesvirus
agent seems to be particularly interesting in consideration of its ability to inactivate the virus and
to inhibit the cell-to-cell virus diffusion.
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Background
Primary and secondary manifestations of infections sus-
tained by herpes simplex viruses (HSVs) are among the
most prevalent human maladies and HSVs are among the
wide range of organisms which cause opportunistic infec-
tions in patients with AIDS and in patients who are immu-
nosupressed because of other iatrogenic or pathologic
reasons, such as organ transplantation or hematologic
malignancies [1]. The emergence of drug-resistant strains
of HSV, especially in immunosupressed patients, is a
major problem and represents a serious concern both in
terms of clinical management and of viral ecology [2-4].
Resistance to all major anti-herpetic drugs, such as acyclo-
vir, vidarabine and foscarnet, has been increasingly
observed [5-7]. Furthermore, DNA polymerase mutants
induced by prolonged or repeated therapy with vidarab-
ine or foscarnet are often resistant also to combination
therapy with existing compounds [8-10]. These observa-
tions underscore the importance of exploring new and
alternative prophylactic and therapeutic tools for the
treatment of herpes simplex infections [11,12].
Many plant extracts have been described as potential anti-
viral agents [13]. Recent reports showed interesting results
of antiviral activity of plant extracts in experimental and
clinical medicine [14,15] and we have previously demon-
strated the antiviral activity in vitro of the essential oil
obtained from Santolina insularis against HSV-1 and -2
[16].
Artemisia  species are widespread in nature and are fre-
quently employed for the treatment of several diseases
such as malaria, hepatitis, cancer, inflammation and
infections sustained by fungi or bacteria [17]. In particu-
lar,  A. annua is known as a remedy for various fevers
including malaria [18] and A. afra, A. giraldii and A. mexi-
cana have been described for their antibacterial activity
[19-22]. Furthermore, a methanolic extract of A. caruifolia
was found to inhibit HIV-1 protease and it was demon-
strated that this inhibition is due to the presence of tri-p-
coumaroylspermidine [23]. The ethanolic and aqueous
extracts of A. arborescens have been investigated for several
biological activities [24], but until now the antiviral prop-
erties of the essential oil against HSV-1 and HSV-2 have
not been described.
Methods
Essential oil
Leaves from Artemisia arborescens were collected in Sar-
dinia (Italy), identified and voucher specimens deposited
in the herbarium of the Institute of Botany and Botanical
Garden, University of Cagliari, Italy. Up to 1500 g of fresh
leaves were distilled in a Clevenger-type apparatus for 5 h,
the essential oil was dried over anhydrous sodium sulfate
and stored at 4°C until use. For the experiments, the oil
was dissolved in dimethyl sulfoxide (DMSO) and there-
fore diluted in the medium. To avoid toxicity or interfer-
ence by the solvent, the maximum concentration of
DMSO in the test medium was 1%.
Virus and cells
African green monkey kidney cells (Vero) were obtained
from the Istituto Zooprofilattico Sperimentale della Lom-
bardia e dell'Emilia (Brescia, Italy). Cells were grown in
RPMI 1640 (Gibco) supplemented with 10% fetal calf
serum (FCS, Gibco) and penicillin, streptomycin and fun-
gizone (100 U/ml, 100 μg/ml, and 2.5 μg/ml, respec-
tively). Overlay medium for the plaque assays of HSV
consisted of Modified Eagle Medium (MEM) without phe-
nol red (Gibco) plus 2% FCS containing antibiotics as
described above and 0.5% agarose.
The strains of HSV type 1 (HSV-1 strain F) and HSV type
2 (HSV-2 strain G) used in this study were obtained from
the American Type Culture Collection (ATCC), Rockville,
Md. HSV-1 and HSV-2 were propagated in Vero cells.
Virus titers were determined by plaque assay in Vero cells
and are expressed as plaque forming units (PFU)·ml-1.
The viruses were stored at -70°C until use.
Cellular toxicity
Cellular toxicity of A. arborescens essential oil was tested in
vitro according to a cell viability assay previously reported
[25,26]. Monolayers of Vero cells in 96-multiwell plates
were incubated with the essential oil at concentration of
1000 – 15.6 μg/ml in RPMI 1640 for 48 h and the
medium replaced with 50 μl of a 1 mg/ml solution of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide, Sigma) in RPMI without phenol red (Sigma).
Cells were incubated at 37°C for 3 h, the untransformed
MTT removed and 50 μl of acid-isopropanol (HCl 0.04 N
in isopropanol) was added to each well. After a few min-
utes at room temperature to ensure that all crystals were
dissolved, the plates were read using an automatic plate
reader with a 570 nm test wavelength and a 690 nm refer-
ence wavelength.
Maximum Non Toxic Dose (MNTD) was determined
microscopically by the observation for morphological
changes of cells at 24, 48 and 72 hours of incubation.
Plaque reduction assay
A. arborescens essential oil was first tested for antiviral
activity against HSV-1 and HSV-2 by a plaque reduction
assay with monolayer cultures of Vero cells grown in
RPMI. Cells were infected with 200–250 PFU of HSV-1 or
HSV-2. After 1 h adsorption at 37°C plates were washed
and medium replaced with MEM containing agarose
0.5%, FCS 2% and different concentrations of essential
oil. After 72 h incubation monolayers were fixed withAnnals of Clinical Microbiology and Antimicrobials 2007, 6:10 http://www.ann-clinmicrob.com/content/6/1/10
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10% formaldehyde in phosphate buffered saline (PBS),
nutrient agar was removed, and cells stained with a 1%
solution of crystal violet in methanol 70%.
Some experiments were also performed incubating about
200–250 PFU of HSV-1 and HSV-2 with A. arborescens
essential oil at concentrations of 100 – 0.19 μg/ml at
37°C or 4°C for varying time periods up to 2 h. Viruses
were then adsorbed at 37°C on Vero cells for 1 h, cells
were washed and medium replaced with MEM containing
agarose 0.5% and FCS 2%. After 72 h incubation at 37°C
monolayers were fixed and processed as described above.
The IC50 values were calculated by regression analysis of
the dose response curves generated from the data.
Inhibition of plaque development assay
Reduction of plaque development assays were performed
as previously described [27] with some modification.
Monolayers of Vero cells were infected with about 100
PFU of HSV-1 or HSV-2 for 3 h at 37°C. Cells were then
washed and the medium was replaced with nutrient agar
containing 100, 50, 25, 12.5 and 6.25 μg of essential oil
per ml and 10 μg/ml of HSV-1 and -2 neutralizing anti-
body (Chemicon International Inc., Temecula, CA) to
ensure that plaque development was actually due to cell-
to cell virus spread. After 48, 72 and 96 h, the plates were
fixed with 10% formaldehyde in PBS for 30 min, the
nutrient agar overlay was removed, and the cells were
stained with 1% solution of crystal violet in 70% metha-
nol for 30 min. The stained monolayers were then washed
and plaque diameter was measured with a digital caliper
(Mitutoyo, Japan). Reduction of plaque size by 50% was
considered positive inhibition. At least 30 plaques were
measured per well. Plaques < 0,2 mm in diameter were
considered abortive and therefore were not counted.
Yield reduction assay
Monolayers of Vero cells grown in 6-well plates were
infected by adsorption of HSV-1 or HSV-2 at a multiplicity
of infection (MOI) of 1 plaque forming unit per cell (PFU/
cell) for 1 h at 37°C. Cells were washed with warm
medium and A. arborescens essential oil at concentrations
ranging between 100 and 3.12 μg/ml in minimum essen-
tial medium with 2% FCS was added immediately after
adsorption. At 24 h after virus inoculation, cells in the cul-
ture medium were lysed by freezing and thawing (three
times), and supernatant consisting of culture medium and
cell lysate was obtained by centrifugation at 400 × g for 10
min at 4°C. Virus titer was determined by plaque forming
assay in Vero cells as described above.
Attachment assay
Vero monolayers grown in 6-well plates were prechilled at
4°C for 15' and infected with HSV-1 or HSV-2 diluted in
serum-free MEM to 200 PFU/ml for varying time periods
up to 3.0 h at 4°C in the presence or absence of serial dilu-
tions of A. arborescens essential oil (40, 20, 10, 5 and 2.5
μg/ml). Unadsorbed virus was then removed and cells
overlaid with nutrient agar. After 72 h cells were fixed and
stained as described above.
Penetration assay
Penetration assays were performed using published proce-
dures with modifications [28]. Briefly, about 200 PFU of
HSV-1 or HSV-2 were adsorbed on Vero cells grown on 6-
well plates for 3 h at 4°C. The medium was replaced with
pre-warmed fresh medium containing A. arborescens
essential oil (final concentrations 40, 20, 10, 5 and 2.5 μg/
ml) and the temperature was abruptly increased to 37°C
to maximize penetration of virus. Penetration proceeded
for various time period (30 min., 1 h, 1.5 h and 2 h). Mon-
olayers were then treated with PBS, pH 3 for 1 min to neu-
tralize any remaining attached virus and after several
washes with serum-free medium cells were overlaid with
MEM-0.5% agarose to quantitate surviving virus versus
time of essential oil exposure.
Post-attachment virus neutralization assay
Post-attachment virus neutralization assays were carried
out using published procedures with modifications
[29,30]. About 250 PFU of HSV-1 and HSV-2 in 0.5 ml of
MEM were adsorbed to Vero cells for 2 h at 4°C. Cells
were then washed, medium replaced with DMEM con-
taining the essential oil of A. arborescens (100 – 12.5 μg/
ml) and incubated for 2 h at 4°C. Cell monolayers were
again washed and overlaid with DMEM containing 0.5%
agarose and incubated at 37° until plaques were fully
developed. As a control, HSV-1 and HSV-2 were incubated
with serial dilutions of the essential oil for 2 h at 4°C prior
to adsorption to cells (pre-attachment neutralization).
Cells were fixed and stained as described above, and the
number of plaques obtained with control HSV-1 and
HSV-2 pretreated with the essential oil was compared with
the number of plaques obtained when the essential oil
was added after adsorption.
Antibacterial and antifungal activity
A. arborescens essential oil was tested for its antibacterial
activity by twofold dilution method in Mueller Hinton
Agar (Difco Laboratories) according to standard proce-
dures against five Gram positive (S. aureus, S. epidermidis,
S. faecalis, S. agalactiae and B. subtilis) and six Gram nega-
tive species (E. coli, P. aeruginosa, K. pneumoniae, S. marces-
cens,  S. typhi and  P. mirabilis) isolated from clinical
specimens. The antifungal activity was evaluated against
C. albicans ATCC E10231 in Sabouraud Dextrose agar. For
the evaluation of antimicrobial activity, concentrations of
essential oil ranging between 500 and 3.9 μg/ml were
employed.Annals of Clinical Microbiology and Antimicrobials 2007, 6:10 http://www.ann-clinmicrob.com/content/6/1/10
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Results and Discussion
Cellular toxicity
The CC50 of A. arborescens essential oil against Vero cells,
determined by the MTT reduction assay on confluent
monolayers, was 132 μg/ml. The MNTD was determined
at 100 mg/ml and this concentration was used as the high-
est dose in the antiviral assays.
Antiviral activity
The activity of A. arborescens essential oil against HSV-1
and HSV-2 was first evaluated by a plaque reduction assay.
When HSV-1 and HSV-2 were exposed to the essential oil
for 1 h at 37°C, A. arborescens exhibited a concentration-
dependent inhibition of plaque formation compared with
the controls (Fig. 1). A 50% inhibition of plaque forma-
tion was observed at 2.4 μg/ml and a 80% inhibition at
5.6 μg/ml against HSV-1, while for HSV-2 the 50% and
80% inhibition values were determined at 4.1 and 7.3 μg/
ml, respectively. HSV-1 inactivation was clearly depend-
ent on the length of the exposure to the essential oil (Fig.
2), and an higher inhibition was observed when HSV-1
was pre-incubated for 2 h at 37°C (50% and 80% inhibi-
tion of plaque formation at 1.14 μg/ml and 2.6 μg/ml,
respectively). Furthermore, inactivation was also depend-
ent on the temperature, since pre-incubating HSV-1 for 1
h at 4°C before virus adsorption 50% and 80% inhibition
values increased to 19.4 μg/ml and 32.2 μg/ml (Fig. 3).
No inhibition was observed by plaque reduction assay
when cells were infected with untreated HSV-1 or HSV-2
and then overlaid with nutrient agar containing essential
oil. Furthermore, no inhibition was observed when cells
were pre-incubated with the essential oil and then
infected with untreated HSV-1 or HSV-2.
Yield reduction assay
Yield reduction assay showed a dose-dependent antiviral
activity of A. arborescens essential oil against HSV-2, even
if inhibition occurred at concentrations much higher than
those needed for neutralization assay. A 70.4% inhibition
was observed at a concentration of 100 μg/ml, and a
38.2% inhibition was still observed at 50 μg/ml (data not
shown). No antiviral activity against HSV-1 was detected
by yield reduction assay.
Inhibition of plaque development assay
Since it is generally agreed that infectious foci develop
when virus infection spreads from infected cells to neigh-
boring uninfected cells, we evaluated the ability of A. arbo-
rescens  to inhibit plaque development when added to
cultures of already infected cells. In Figure 4 and Figure 5
are reported results obtained when Vero cells infected
with HSV-1 or HSV-2 were overlaid with nutrient agar
containing A. arborescens essential oil at 100 – 6.25 μg/ml
and incubated at 37°C in the presence of neutralizing
antibody to ensure that plaque development was actually
due to cell-to-cell spread. A concentration-dependent
reduction of plaque size was observed for both HSV-1 and
HSV-2. In particular, a 68.3% inhibition of HSV-1 lateral
diffusion was detected after 96 h incubation in the pres-
ence of essential oil 100 μg/ml and a 67.1% inhibition
was observed after 48 h incubation with a concentration
of 50 μg/ml. A significant reduction of plaque develop-
ment was shown also by lower concentrations of A. arbo-
rescens. A statistically significant reduction of plaque
diameter was observed for HSV-2, and in particular after
48 h incubation a 55.9% reduction was observed at 100
μg/ml and a 21.7% reduction respect to the untreated
controls was still observed at 12.5 μg/ml (Fig. 5).
Attachment, penetration and post-attachment virus 
neutralization assays
Virus attachment was inhibited at concentrations of
essential oil higher than 50 μg/ml, thus much higher than
the doses needed to inactivate the controls of HSV-1 and
HSV-2 pre-incubated for 2 h at 4°C in the presence of A.
arborescens, indicating that attachment was not affected
and effects were mainly due to a direct effect on the virion.
Furthermore, no inhibition was observed by penetration
assay and no inhibition with respect to the controls was
Effects of A. arborescens essential oil on plaque formation by  HSV-1 and HSV-2 Figure 1
Effects of A. arborescens essential oil on plaque formation by 
HSV-1 and HSV-2. About 250 PFU of HSV-1 (black circle) or 
HSV-2 (black square) were pre-incubated for 1 h at 37°C in 
the presence of serial dilutions of essential oil and then 
adsorbed on Vero cells. A. arborescens showed a 50% inhibi-
tion of plaque formation respect to the controls at 2.4 μg/ml 
and a 80% inhibition at 5.6 μg/ml, while against HSV-2 a 50% 
and 80% were observed at 4.1 μg/ml and 7.3 μg/ml, respec-
tively. The data represent the means for five replicate sam-
ples of three separate experiments.
0,1 1 10 100
0
20
40
60
80
100
%
o
f
i
n
h
i
b
i
t
i
o
n
A. arborescens essential oil [μ g/ml]Annals of Clinical Microbiology and Antimicrobials 2007, 6:10 http://www.ann-clinmicrob.com/content/6/1/10
Page 5 of 7
(page number not for citation purposes)
detected by post-attachment virus neutralization assay.
The number of plaques obtained following adsorption of
HSV-1 and HSV-2 in Vero cells at 4°C and incubation, still
at 4°C, in the presence of A. arborescens was comparable
to the number of plaques obtained pre-incubating the
viruses alone at 4°C in the presence of the essential oil
before virus adsorption (data not shown).
Antibacterial and antifungal activity
No inhibition of growth of the tested bacteria and C. albi-
cans ATCC E10231 was observed at a concentration of A.
arborescens essential oil of 500 μg/ml after 24 h incubation
at 37°C.
Conclusion
The study has demonstrated the antiviral activity against
HSV-1 and HSV-2 of the essential oil in toto obtained from
A. arborescens. Experiments of plaque reduction assay
showed a concentration-dependent inhibition of the
plaque formation when the viruses were exposed to the
essential oil before adsorption with IC50 of 2.4 and 4.1 μg/
ml for HSV-1 and HSV-2, respectively, therefore at con-
centrations much lower than the cytotoxic dose for Vero
cells (CC50 132 μg/ml), indicating a CC50/IC50 ratio of 55
and 32.2 for HSV-1 and HSV-2. No reduction of the
number of plaques was detected when the essential oil
Inhibition of plaque development assay Figure 4
Inhibition of plaque development assay. A. arborescens essen-
tial oil was applied 3 h post-infection on monolayer of Vero 
cells infected with 100 PFU of HSV-1. A concentration-
dependent reduction of plaque development was observed at 
48, 72 and 96 h post-infection. The data represent the means 
for three replicates of three separate experiments.
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Direct inactivation of different concentrations of A. arbores- cens essential oil on HSV-1 at various times as determined by  plaque reduction assay Figure 2
Direct inactivation of different concentrations of A. arbores-
cens essential oil on HSV-1 at various times as determined by 
plaque reduction assay. HSV-1 was mixed with A. arborescens 
essential oil and incubated for 15 min. (black circle), 1 h 
(black square) or 2 h (white circle) at 37°C. IC50 of 2.4 μg/ml 
as determined after 1 h pre-incubation at 37°C, shifted to 
1.14 μg/ml and 6.9 μg/ml when HSV-1 was pre-incubated for 
2 h or 15 min, respectively. Results are presented as mean 
percentage of control of three separate experiments.
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Neutralizing activity of A. arborescens essential oil against  HSV-1 as determined by plaque reduction assay after 1 h pre- incubation at 37°C (black square) or 4°C (black circle) Figure 3
Neutralizing activity of A. arborescens essential oil against 
HSV-1 as determined by plaque reduction assay after 1 h pre-
incubation at 37°C (black square) or 4°C (black circle). IC50 
of 2.4 μg/ml as determined after 1 h pre-incubation at 37°C, 
increased to 19.4 μg/ml when HSV-1 was pre-incubated for 
the same time at 4°C. Results are presented as mean per-
centage of control of four separate experiments.
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was added to monolayers of already infected cells, indicat-
ing that antiviral activity of A. arborescens is essentially due
to direct virucidal effects. Furthermore, virus attachment
and penetration were not affected and no effects were
observed by post-attachment virus neutralization assay.
Experiments of yield reduction assay indicated that at
higher concentrations A. arborescens also inhibited the
replication of HSV-2 and a significant reduction of cell-to-
cell virus spread, as determined by inhibition of plaque
development assay, was observed for both HSV-1 and
HSV-2. These two aspects are particularly interesting and
indicate that the antiviral activity of A. arborescens is not
only due to direct virucidal effects, but other mechanisms
are involved.
The nature and the mechanism of action of the active
components of the essential oil is presently unknown and
further studies are in progress to isolate the compounds
involved in the antiviral activity of A. arborescens. Other
investigators indicated the presence in extracts of Artemisia
species of flavones such as 4',6,7-trihydroxy-3',5'-dimeth-
oxyflavone and 5',5-dihydroxy-3',4',8-trimethoxyflavone
[19], exiguaflavone A and B [31], artemetin, bonanzin,
eupalitin and chrysosplenetin [32]. Flavones have been
extensively described for their antiviral activity [33] and it
was demonstrated that the anti-HSV-1 activity is not due
to the inhibition of virus adsorption, penetration and
viral protein synthesis [34], but involves a virucidal activ-
ity which results in a prevention of virus adsorption to
host cells and subsequent replication. Therefore, flavones
might be responsible, at least in part, for the antiviral
activity of A. arborescens. Since the essential oil showed
IC50 values against HSV-1 and HSV-2 much lower than
IC50 showed by flavones tested alone [34,35], it might be
supposed that some synergism between the components
of the essential oil occurs. Furthermore, it is interesting
point out that flavones obtained from other Artemisia spe-
cies showed a significant antibacterial and antifungal
activities, while no antimicrobial activity by A. arborescens
essential oil occurred when tested against bacteria and
fungi even at concentrations as high as 500 μg/ml.
Several essential oils have been studied for their activity
against HSV-1 and -2 and have been proposed as promis-
ing alternative therapeutic tools [13,16,36]. In fact, since
their activity is commonly due to a direct virion inactiva-
tion, these oils are often effective also against acyclovir-
resistant strains [37]. In comparison with already
described essential oils, the mode of action of A. arbores-
cens essential oil as antiherpesvirus agent is particularly
interesting not only in consideration of its ability to inac-
tivate the extracellular virus at concentration much lower
than those described for other essential oils, but also for
its ability to inhibit the cell-to-cell virus diffusion in
already infected cells. Results obtained encourage further
investigations in order to isolate and characterize the
compound responsible for the antiviral activity of the
essential oil.
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